IBI Ag Completes $10 Million Series A Round Led by Corteva
IBI Ag (private) completed the second and final tranche of its $10 million Series A on November 11, 2025, led by Corteva through its Corteva Catalyst platform.
Participants included The Trendlines Group (TRNLY), Iron Nation, Consensus Business Group, Bandera Capital, First Imagine Ventures, and a grant from the Israel Innovation Authority. The funds are intended to accelerate product development and regulatory advancement for IBI Ag's antibody-based (nanobody) bioinsecticide platform, targeting sucking and chewing pests while aiming to reduce ecological impact and preserve beneficial species.
IBI Ag (privata) ha completato la seconda e ultima tranche del suo Series A da 10 milioni di dollari il 11 novembre 2025, guidata da Corteva tramite la sua piattaforma Corteva Catalyst.
Partecipanti includevano The Trendlines Group (TRNLY), Iron Nation, Consensus Business Group, Bandera Capital, First Imagine Ventures e una sovvenzione dall'Israel Innovation Authority. I fondi sono destinati ad accelerare lo sviluppo del prodotto e l'avanzamento normativo per la piattaforma bioinsetticida basata su anticorpi (nanobody) di IBI Ag, mirata a insetti succhiatori e masticatori, con l'obiettivo di ridurre l'impatto ecologico e preservare le specie utili.
IBI Ag (privada) completó la segunda y última etapa de su Series A de 10 millones de dólares el 11 de noviembre de 2025, liderada por Corteva a través de su plataforma Corteva Catalyst.
Entre los participantes se encontraban The Trendlines Group (TRNLY), Iron Nation, Consensus Business Group, Bandera Capital, First Imagine Ventures y una subvención de la Israel Innovation Authority. Los fondos se destinarán a acelerar el desarrollo del producto y el avance regulatorio de la plataforma bioinsecticida basada en anticuerpos (nanobodies) de IBI Ag, dirigida a plagas chupadoras y masticadoras, con el objetivo de reducir el impacto ecológico y conservar las especies beneficiosas.
IBI Ag(비상장 기업)은 1000만 달러 규모의 Series A의 두 번째이자 최종 tranche를 2025년 11월 11일에 마쳤고, Corteva Catalyst 플랫폼을 통해 Corteva가 주도했습니다.
참여 기업으로는 The Trendlines Group (TRNLY), Iron Nation, Consensus Business Group, Bandera Capital, First Imagine Ventures, 그리고 Israel Innovation Authority의 보조금이 포함됩니다. 자금은 IBI Ag의 항체 기반(나노바디) 생물살충제 플랫폼의 제품 개발과 규제 승인을 가속화하는 데 사용되며, 흡식 및 절식 해충을 표적으로 삼고 생태계 영향 감소 및 유익한 종의 보전을 목표로 합니다.
IBI Ag (privée) a achevé la deuxième et dernière tranche de son levier Series A de 10 millions de dollars le 11 novembre 2025, dirigée par Corteva via sa plateforme Corteva Catalyst.
Les participants incluaient The Trendlines Group (TRNLY), Iron Nation, Consensus Business Group, Bandera Capital, First Imagine Ventures, et une subvention de Israel Innovation Authority. Les fonds sont destinés à accélérer le développement du produit et l'avancement réglementaire de la plateforme bioinsecticide à base d'anticorps (nanobodies) de IBI Ag, ciblant les insectes suceurs et masticateurs, tout en visant à réduire l'impact écologique et à préserver les espèces bénéfiques.
IBI Ag (privat) hat die zweite und letzte Tranche seiner 10-Millionen-Dollar-Series-A am 11. November 2025 abgeschlossen, geleitet von Corteva über dessen Corteva Catalyst-Plattform.
Zu den Teilnehmern gehörten The Trendlines Group (TRNLY), Iron Nation, Consensus Business Group, Bandera Capital, First Imagine Ventures und ein Zuschuss der Israel Innovation Authority. Die Mittel sollen die Produktentwicklung und regulatorische Fortschritte für die antikörperbasierte (Nanobody) Bioinsektizid-Plattform von IBI Ag beschleunigen, die auf Sau- und Fressschädlinge abzielt und darauf abzielt, die ökologische Auswirkung zu verringern und nützliche Arten zu erhalten.
IBI Ag (خاص) أكملت الشريحة الثانية والأخيرة من جولة التمويل Series A بقيمة 10 ملايين دولار في 11 نوفمبر 2025، بقيادة Corteva من خلال منصة Corteva Catalyst.
وشمل المشاركون The Trendlines Group (TRNLY)، Iron Nation، Consensus Business Group، Bandera Capital، First Imagine Ventures، ومنحة من Israel Innovation Authority. يهدف التمويل إلى تسريع تطوير المنتج والتقدم التنظيمي لمنصة مبيد حشري حيوي قائم على الأجسام المضادة (نانوبادِي) من IBI Ag، يستهدف الآفات الشفاشة والمضغّة مع السعي لتقليل الأثر البيئي والحفاظ على الأنواع المفيدة.
- $10.0M Series A completed (final tranche) on Nov 11, 2025
- Led by Corteva Catalyst with strategic industry partner support
- Participation from Trendlines (TRNLY), investors, and an Israel Innovation Authority grant
- Funds designated to accelerate product development and regulatory advancement
- None.
This is the second and final tranche of IBI Ag's Series A Round for its novel bioinsecticide platform
NESS ZIONA,
The investment was led by Corteva ("Corteva") through its Corteva Catalyst platform, with the participation of The Trendlines Group (SGX:42T) (OTCQX: TRNLY), Iron Nation, Consensus Business Group ("CBG"), and a grant from the Israel Innovation Authority, joined by Bandera Capital and First Imagine Ventures, enabling the closing of the round.
The completion of this Series A represents a significant milestone for IBI Ag, underscoring growing global recognition of the company's innovative antibody-based bioinsecticide platform. The funds will enable IBI Ag to accelerate product development and regulatory advancement of its next-generation biological pest control solutions.
IBI Ag's proprietary technology leverages single-domain antibodies (nanobodies) to create highly effective, selective, and safe biological insect control products. Adapted from the pharmaceutical field and optimized for agriculture, this groundbreaking platform introduces new modes of action that protect high-value crops from both sucking and chewing insects, while minimizing environmental impact and preserving beneficial species.
"We're proud to have the continued confidence of our investors and to welcome Bandera Capital and First Imagine Ventures to the IBI Ag family," said Arnon Heyman, CEO of IBI Ag. "With the completion of our Series A, we are well positioned to bring our novel biological solutions closer to farmers worldwide, supporting both productivity and sustainability."
"The collaboration between IBI Ag and Corteva is a clear example of how working together can deliver innovation that increases performance and provides more sustainable solutions in crop protection," said Tom Greene, senior director at Corteva and global leader for Corteva Catalyst. "We are excited to continue exploring the development of next generation biologicals and naturally inspired solutions as IBI Ag advances toward commercialization."
Corteva, through its Corteva Catalyst platform, collaborates with entrepreneurs and innovators to accelerate the development of early-stage, disruptive technologies that enable farmers to sustainably produce more food and feed.
About IBI Ag
IBI Ag is a pioneer in the Agri-biotech industry, developing innovative and sustainable crop protection solutions. The company's proprietary nanobody technology provides a new mode of action for controlling a broad range of insect pests with minimal ecological footprint. Founded by The Trendlines Group together with Dr. Amir Ayali and Dr. Rony Oren Benaroya, and supported by the Israel Innovation Authority, IBI Ag is redefining the future of pest management.
Media Contact:
Arnon Heyman, CEO – IBI Ag
Email: Arnon.heyman@ibi-ag.com
Logo - https://mma.prnewswire.com/media/2818692/IBIAG_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/ibi-ag-completes-10-million-series-a-round-led-by-corteva-302611427.html
SOURCE IBI Ag
FAQ
What did IBI Ag announce about its Series A funding on November 11, 2025?
How is The Trendlines Group (TRNLY) involved in IBI Ag's Series A round?
What will the $10 million Series A funds be used for at IBI Ag?
Which strategic partner led IBI Ag's Series A and why does it matter for commercialization?
Did IBI Ag receive government support as part of the Series A financing?
